Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Poster Presentation | Jun 12, 2025

Author

Aldoss I, et al.

Congress

European Hematology Association Annual Congress 2025

Milan, Italy | June 12 – 15, 2025